Immutep’s newly announced partnership with India-based pharmaceutical group Dr Reddy’s marks a milestone moment for the company, representing the first commercialisation step for efti in emerging markets.
Dr Reddy’s—an international player with more than 27,000 employees and a market value of about US$12bn—will take responsibility for commercialising efti across emerging markets, while Immutep retains rights to key territories including North America, Europe, Japan and Greater China. The structure preserves upside optionality for Immutep while providing what the company describes as a “one-stop solution” for the remaining global markets.
Under the agreement, Immutep will receive a US$20m upfront payment and may earn up to US$349.5m in additional milestone payments, alongside double-digit royalties once sales commence.
CEO and Executive Director Marc Voigt frames the transaction as commercially attractive and strategically significant, especially given it was secured prior to full recruitment or data readouts from the pivotal TACTI-004 study. He also emphasises that the deal reflects years of relationship-building and due diligence, and highlights Dr Reddy’s recent experience launching an anti-PD-1 therapy in Australia as evidence of its capability to bring efti to patients across emerging markets.
